References
- Dementia statistics. Available from: http://www.alz.co.uk/research/statistics
- World Alzheimer Report 2015. The global impact of dementia, an analysis of prevalence, incidence, cost and trends. Available from: http://www.alz.co.uk/research/WorldAlzheimerReport2015-sheet.pdf.
- Schneider, L.S., F. Mangialasche, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251–283.
- Fan LY, Chiu MJ. Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2014;10:439–451.
- Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
- Bertram L, Tanzi RE. The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci. 2012;107:79–100.
- Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–388.
- Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med. 2011;17(9):1060–1065.
- Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Rev Neurother. 2009;9(5):661–679.
- Khan A, Ballard CB. Emerging amyloid and tau targeting treatments for Alzheimer’s disease. 2017. Accepted in Exp. Rev. of Neurother. 2017.
- Caring for a person with dementia. drug treatments. Available from: https://www.alz.co.uk/caring/drug-treatments.
- Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.
- Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2009;2:CD001191.
- Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
- Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
- Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;18:5.
- Suh DC, Arcona S, Thomas SK, et al. Risk of antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine. Drugs Aging. 2004;21(6):395–403.
- Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer’s disease in managed care. Am J Geriatr Pharmacother. 2006;4(Suppl A):S9-S24; quiz S25-S28.
- Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Cmaj. 2002;167(11):1269–1270.
- Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Cmaj. 2004;170(9):1395.
- Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Jama. 2005;293(5):596–608.
- Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.
- Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–157.
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 2005;294(15):1934–1943.
- Scharre DW, Vekeman F, Lefebvre P, et al. Use of antipsychotic drugs in patients with Alzheimer’s disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. Drugs Aging. 2010;27(11):903–913.
- Narayanan S, Beusterien KM, Thomas SK, et al. Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc. 2006;7(1):12–16.
- Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(12):1515–1528.
- Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics. 2008;5(3):458–469.
- Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010;13(8):1021–1033.
- Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092–1099.
- Study of Lu AE58054 in patients with mild - moderate Alzheimer’s disease treated with donepezil (STARSHINE). Available from: https://www.clinicaltrials.gov/show/NCT01955161.
- Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil (STARBEAM). Available from: https://www.clinicaltrials.gov/show/NCT02006641.
- Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor (STARBRIGHT). Available from: https://www.clinicaltrials.gov/show/NCT02006654.
- Long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer’s disease (STAR Extension). Available from: https://www.clinicaltrials.gov/show/NCT02079246.
- de Bruin NM, van Drimmelen M, Kops M, et al. Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. Behav Brain Res. 2013;244:15–28.
- Callaghan CK, Hok V, Della-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology. 2012;63(5):890–897.
- A study of SB-742457, added to donepezil for the treatment of mild-to-moderate Alzheimer’s disease. Available from: https://clinicaltrials.gov/show/NCT00710684.
- Study of SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease. Available from: https://clinicaltrials.gov/show/NCT00708552.
- Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr Alzheimer Res. 2010;7(5):374–385.
- Codony X, Vela JM, Ramirez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11(1):94–100.
- Bhattacharya S, Maelicke A, Montag D. Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer’s disease mice. J Alzheimers Dis. 2015;46(1):123–136.
- Maelicke A, Hoeffle-Maas A, Ludwig J, et al. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci. 2010;40(1–2):135–137.
- Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer’s disease. Amyloid. 2003;10(1):1–6.
- Caccamo A, Fisher A, LaFerla FM. M1 agonists as a potential disease-modifying therapy for Alzheimer’s disease. Curr Alzheimer Res. 2009;6(2):112–117.
- Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671–682.
- Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease–an update. Curr Alzheimer Res. 2007;4(5):577–580.
- Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465–473.
- Foster DJ, Choi DL, Conn PJ, et al. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183–191.
- Rare but severe side effects sideline some phase 3 encenicline trials. Available from: http://www.alzforum.org/news/research-news/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials.
- Puri V, Wang X, Vardigan JD, et al. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer’s disease mouse model. Behav Brain Res. 2015;287:96–99.
- Lange HS, Cannon CE, Drott JT, et al. The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys. J Pharmacol Exp Ther. 2015;355(3):442–450.
- Efficacy and Safety of MK-7622 as adjunct therapy in participants with Alzheimer’s disease (MK-7622-012). Available from: https://www.clinicaltrials.gov/show/NCT01852110.
- Villard V, Espallergues J, Keller E, et al. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101–1117.
- Lahmy V, Meunier J, Malmstrom S, et al. Blockade of Tau hyperphosphorylation and Abeta(1)(-)(4, 2) generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2013;38(9):1706–1723.
- Phase 2a dose finding, PK/PD and 12 month exploratory efficacy study of ANAVEX2-73 in patients with Alzheimer’s disease. Available from: https://clinicaltrials.gov/show/NCT02244541.
- Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16(17):2581–2588.
- A study of two fixed-doses of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer’s type. Available from: https://www.clinicaltrials.gov/show/NCT01862640.
- Safety and tolerability study of flexible dosing of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer’s type. Available from: https://www.clinicaltrials.gov/show/NCT01922258.
- Kalkman HO, Loetscher E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol. 2003;462(1–3):33–40.
- Orion Corporation presented promising Phase II data for new Alzheimer’s disease drug at AAN annual meeting. Available from: http://www.orion.fi/en/Orion-group/media/press-releases/2013/orion-corporation-presented-promising-phase-ii-data-for-new-alzheimers-disease-drug-at-aan-annual-meeting/.
- Efficacy of ORM-12741 on agitation/aggression symptoms in Alzheimer’s Disease (Nebula). Available from: https://clinicaltrials.gov/ct2/show/NCT02471196.
- Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 2014;311(7):682–691.
- Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–1254.
- Chappell AS, Gonzales C, Williams J, et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology. 2007;68(13):1008–1012.
- Trzepacz PT, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. Int Psychogeriatr. 2013;25(5):707–719.
- Eubanks LM, Rogers CJ, Beuscher AET, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm. 2006;3(6):773–777.
- Cao CH, Li YQ, Liu H, et al. The potential therapeutic effects of THC on Alzheimer’s disease. J Alzheimers Dis. 2014;42(3):973–984.
- Trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD). Available from: https://clinicaltrials.gov/ct2/show/NCT02792257.
- Safety and efficacy of nabilone in Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02351882.
- Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease. Pharmaceuticals (Basel). 2013;6(10):1304–1321.
- Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov. 2012;11(11):833–846.
- Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72(5):603–612.
- Li L, Zhang ZF, Holscher C, et al. (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol. 2012;674(2–3):280–286.
- Wang XH, Li L, Holscher C, et al. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience. 2010;170(4):1239–1248.
- McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31(17):6587–6594.
- Hamilton A, Patterson S, Porter D, et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89(4):481–489.
- Evaluating Liraglutide in Alzheimer’s disease (ELAD). Available from: https://clinicaltrials.gov/ct2/show/NCT01843075.
- A pilot clinical trial of exendin-4 in Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01255163.
- Wright JW, Harding JW. Brain renin-angiotensin–a new look at an old system. Prog Neurobiol. 2011;95(1):49–67.
- Culman J, Blume A, Gohlke P, et al. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens. 2002;16(Suppl 3):S64–70.
- Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010;13(2–3):195–201.
- Reducing pathology in Alzheimer’s disease through angiotensin targeting. Available from: http://www.isrctn.com/ISRCTN93682878.
- Telmisartan vs. perindopril in hypertensive mild-moderate Alzheimer’s disease patients (SARTAN-AD). Available from: https://clinicaltrials.gov/ct2/show/NCT02085265.
- Forloni G, Colombo L, Girola L, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001;487(3):404–407.
- Ryu JK, Franciosi S, Sattayaprasert P, et al. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia. 2004;48(1):85–90.
- Fan R, Xu F, Previti ML, et al. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci. 2007;27(12):3057–3063.
- Cuello AC, Ferretti MT, Leon WC, et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis. 2010;7(1–3):96–98.
- Parachikova A, Vasilevko V, Cribbs DH, et al. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis. 2010;21(2):527–542.
- Minocycline in Alzheimer’s disease efficacy (MADE) trial Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14866.
- Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15(9):1227–1235.
- Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77(6):953–971.
- Safety and tolerability of AZD0530 (Saracatinib) in Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01864655.
- A phase ii a multi-center study of 18F-FDG PET, safety, and tolerability of AZD0530 in mild Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02167256.
- Investigating the potential of a common drug to treat a cause of vascular dementia and contributor to Alzheimer’s disease. Available from: https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=2845.
- Duffy JP, Harrington EM, Salituro FG, et al. The discovery of VX-745: a novel and selective p38alpha kinase inhibitor. ACS Med Chem Lett. 2011;2(10):758–763.
- A PET study of the effects of p38 MAP kinase inhibitor, VX-745, on amyloid plaque load in Alzheimer’s disease (AD). Available from: https://www.clinicaltrials.gov/show/NCT02423122.
- Clinical pharmacology of p38 MAP kinase inhibitor, VX-745, in mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD. Available from: https://www.clinicaltrials.gov/show/NCT02423200.
- Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.
- Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84(3):608–622.
- Weinreb O, Amit T, Bar-Am O, et al. A novel anti-Alzheimer’s disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol. 2011;100:191–215.
- A 3 year study to evaluate the safety and efficacy of low dose ladostigil in patients with mild cognitive impairment (MCI). Available from: http://clinicaltrials.gov/ct2/show/NCT01429623.
- Safety and efficacy study of ladostigil in mild to moderate probable Alzheimer’s disease. Available from: http://clinicaltrials.gov/ct2/show/NCT01354691.
- Available from: http://www.avphar.com/avraham-pharmaceuticals-announces-successful-second-interim-results-in-phase-2b-study-of-ladostigil-for-the-treatment-of-mild-cognitive-impairment/.
- A study of PF-04447943 compared to placebo in subjects with mild to moderate Alzheimer’s disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00930059.
- Schwam EM, Nicholas T, Chew R, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease. Curr Alzheimer Res. 2014;11(5):413–421.
- Available from: www.news-medical.net/news/20090923/, C.-t.t.s.t.p.o.A.s.d. and C.-.-t.-t.-s.-t.-p.-o.-. Alzheimers-disease.aspx.
- Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target. 2009;17(8):564–574.
- Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106(32):13594–13599.
- Peretti D, Bastide A, Radford H, et al. RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. Nature. 2015;518(7538):236–239.
- The safety and the efficacy evaluation of NEUROSTEM®-AD in patients with Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01297218.
- Safety and exploratory efficacy study of NEUROSTEM® versus placebo in patients with Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02054208.
- Safety and efficiency of umbilical cord-derived mesenchymal stem cells(UC-MSC) in patients with Alzheimer’s Disease (SEMAD). Available from: https://clinicaltrials.gov/ct2/show/NCT01547689.
- Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6):456–464.
- Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006;56(2):159–164.
- Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Jama. 2010;304(17):1903–1911.
- Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2008;23(2):161–169.
- Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: omegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402–1408.
- Lloret A, Badia MC, Mora NJ, et al. Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17(1):143–149.
- Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen. 2009;24(1):27–33.
- A multicenter trial of rofecoxib and naproxen in Alzheimer’s disease (NSAID study). Available from: https://clinicaltrials.gov/ct2/show/NCT00004845.
- Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama. 2009;302(23):2557–2564.
- Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev. 2012;2:CD006378.
- Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43(8):1609–1611.
- De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One. 2008;3(1):e1475.
- Study evaluating safety, tolerability, and PK of multiple ascending doses of GC021109 in subjects with mild to moderate Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02386306.
- Schmidt AM, Sahagan B, Nelson RB, et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs. 2009;10(7):672–680.
- Bates KA, Verdile G, Li QX, et al. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14(5):469–486.
- Sturchler E, Galichet A, Weibel M, et al. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci. 2008;28(20):5149–5158.
- Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):206–212.
- A phase 2 study evaluating the efficacy and safety of PF 04494700 in mild to moderate Alzheimer’s disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00566397.
- A phase 2 study evaluating the efficacy and safety of PF 04494700 In mild to moderate Alzheimer’s disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00566397.
- Evaluation of the efficacy and safety of Azeliragon (TTP488) in patients with mild Alzheimer’s disease (STEADFAST). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02080364.
- Zhihui Q. Modulating nitric oxide signaling in the CNS for Alzheimer’s disease therapy. Future Med Chem. 2013;5(12):1451–1468.
- van der Staay FJ, Rutten K, Barfacker L, et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology. 2008;55(5):908–918.
- Vardigan JD, Converso A, Hutson PH, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J Neurogenet. 2011;25(4):120–126.
- Husson M, Enderlin V, Delacourte A, et al. Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis. 2006;23(1):1–10.
- Kroker KS, Rast G, Giovannini R, et al. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology. 2012;62(5–6):1964–1974.
- BI 409306 in patients with cognitive impairment due to Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02337907.
- Alzheimer disease proof of concept study with BI 409306 versus placebo. Available from: https://clinicaltrials.gov/ct2/show/NCT02240693.
- Murphy GM Jr., Yang L, Cordell B. Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem. 1998;273(33):20967–20971.
- Boyd TD, Bennett SP, Mori T, et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis. 2010;21(2):507–518.
- Manczak M, Mao P, Nakamura K, et al. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer’s disease. Hum Mol Genet. 2009;18(20):3876–3893.
- Jim HS, Boyd TD, Booth-Jones M, et al. Granulocyte macrophage colony stimulating factor treatment is associated with improved cognition in cancer patients. Brain Disord Ther. 2012;1(1):1000101.
- Study of the safety & efficacy of Leukine® in the treatment of Alzheimer’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01409915.
- Study to evaluate the safety, tolerability, and pharmacokinetics of ABT-957 in subjects with mild-to-moderate Alzheimer’s disease on stable doses of acetylcholinesterase inhibitors. Available from: https://clinicaltrials.gov/ct2/show/NCT02220738.
- Chen S, Wang JM, Irwin RW, et al. Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer’s disease. PLoS One. 2011;6(8):e24293.
- Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010;107(14):6498–6503.
- Zhang P, Xie MQ, Ding YQ, et al. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice. Neuroscience. 2015;290:214–226.
- Allopregnanolone for mild cognitive impairment due to Alzheimer’s disease or mild AD. Available from: https://clinicaltrials.gov/ct2/show/NCT02221622.
- Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30(10):1574–1586.
- Mosconi L, de Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008;29(5):676–692.
- Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106(34):14670–14675.
- Cardoso SM, Santana I, Swerdlow RH, et al. Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity. J Neurochem. 2004;89(6):1417–1426.
- Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.
- Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;4:CD009524.
- Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.
- Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70(6):440–448.
- (SNIFF)., T.S.o.N.I.i.t.F.A.F. Available from: https://clinicaltrials.gov/ct2/show/NCT01767909.
- Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci. 2004;20(4):896–902.
- Chakrabarti M, McDonald AJ, Will Reed J, et al. Molecular signaling mechanisms of natural and synthetic retinoids for inhibition of pathogenesis in Alzheimer’s disease. J Alzheimers Dis. 2015;50:335–352.
- Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry. 2010;18(10):928–939.
- Yu F, Rose KM, Burgener SC, et al. Cognitive training for early-stage Alzheimer’s disease and dementia. J Gerontol Nurs. 2009;35(3):23–29.
- Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003;183:248–254.
- Owen AM, Hampshire A, Grahn JA, et al. Putting brain training to the test. Nature. 2010;465(7299):775–778.
- Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017–3022.
- Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67(1):71–79.
- Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. Jama. 2008;300(9):1027–1037.
- Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19(3):163–165.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292.
- Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216.
- Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.
- Bateman RJ, Aisen PS, de Strooper B, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3(1):1.
- Panza F, Frisardi V, Seripa D, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev. 2012;11(1):87–103.